New England Journal of Medicine· 2019Q1
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- 3,422citations
- Q1SCImago
- 2019year
Short summary
Pembrolizumab plus axitinib significantly improved overall survival (89.9% alive at 12 months vs. 78.3%), progression-free survival (15.1 months vs. 11.1 months), and objective response rate (59.3% vs. 35.7%) compared to sunitinib in previously untreated advanced renal-cell carcinoma patients.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine